{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:34:41Z","timestamp":1778884481105,"version":"3.51.4"},"reference-count":106,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.hoc.2011.09.006","type":"journal-article","created":{"date-parts":[[2011,11,3]],"date-time":"2011-11-03T07:49:04Z","timestamp":1320306544000},"page":"1009-1023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Selection of Therapy: Rational Decisions Based on Molecular Events"],"prefix":"10.1016","volume":"25","author":[{"given":"Jamshid S.","family":"Khorashad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.N.","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2011.09.006_bib1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2011.09.006_bib2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1586\/ehm.10.61","article-title":"Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study","volume":"3","author":"Giles","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.hoc.2011.09.006_bib3","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib4","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib5","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1590\/S1807-59322009000800004","article-title":"Influence of late treatment on how chronic myeloid leukemia responds to imatinib","volume":"64","author":"Scerni","year":"2009","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.hoc.2011.09.006_bib6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2007.13.2373","article-title":"Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML","volume":"26","author":"Palandri","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.006_bib7","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2011.09.006_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0037-1963(03)70045-6","article-title":"Advanced-phase chronic myeloid leukemia","volume":"40","author":"Cortes","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.hoc.2011.09.006_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1053\/shem.2003.50049","article-title":"Clinical decisions for chronic myeloid leukemia in the imatinib era","volume":"40","author":"Goldman","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.hoc.2011.09.006_bib10","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib11","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib12","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood.V99.10.3547","article-title":"Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase","volume":"99","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib13","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2011.09.006_bib14","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2011.09.006_bib15","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2010.110","article-title":"Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy","volume":"24","author":"Giles","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2011.09.006_bib16","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial","volume":"27","author":"Apperley","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.006_bib17","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1002\/cncr.25123","article-title":"Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily","volume":"116","author":"Saglio","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2011.09.006_bib18","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib19","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib21","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukaemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.006_bib22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1046\/j.1365-2141.1997.102652.x","article-title":"Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal\u2019s index and a new score. German chronic myeloid leukaemia (CML)-Study Group","volume":"97","author":"Hehlmann","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2011.09.006_bib23","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A\u00a0new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.hoc.2011.09.006_bib24","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2009.012781","article-title":"Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"95","author":"Milojkovic","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2011.09.006_bib26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ajh.22020","article-title":"Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors","volume":"86","author":"Breccia","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2011.09.006_bib27","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1182\/blood-2010-07-293977","article-title":"Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure","volume":"117","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib28","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2008-02-141580","article-title":"Failure to achieve a major cytogenetic response by twelve months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib29","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V66.6.1326.1326","article-title":"Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival","volume":"66","author":"Kantarjian","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib30","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1182\/blood.V72.1.294.294","article-title":"Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia","volume":"72","author":"Sokal","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib31","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C","article-title":"Characteristics of accelerated disease in chronic myelogenous leukemia","volume":"61","author":"Kantarjian","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2011.09.006_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0165-4608(87)90161-0","article-title":"Karyotype evolution in CML: high frequency of translocations other than the Ph","volume":"25","author":"Sessarego","year":"1987","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.hoc.2011.09.006_bib33","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.1996.14.1.196","article-title":"Significance of cytogenetic clonal evolution in chronic myelogenous leukemia","volume":"14","author":"Majlis","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.006_bib34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2011.09.006_bib35","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib36","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2003-02-0371","article-title":"Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate","volume":"103","author":"O\u2019Dwyer","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib37","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib38","first-page":"260","article-title":"Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression","volume":"88","author":"Marktel","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2011.09.006_bib39","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/shem.2003.50043","article-title":"Cytogenetic studies in patients on imatinib","volume":"40","author":"Deininger","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.hoc.2011.09.006_bib40","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.006_bib41","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/cncr.25015","article-title":"Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy","volume":"116","author":"Verma","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2011.09.006_bib42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","article-title":"Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML","volume":"107","author":"Yong","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib43","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2011.09.006_bib44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","article-title":"A\u00a0gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib","volume":"115","author":"McWeeney","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib45","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1200\/JCO.2008.19.4076","article-title":"Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance","volume":"27","author":"Zhang","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.006_bib46","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.leu.2404227","article-title":"Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis","volume":"20","author":"Zheng","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2011.09.006_bib47","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/blood-2009-03-212969","article-title":"The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data","volume":"114","author":"Oehler","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib48","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/leu.2008.210","article-title":"Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis","volume":"22","author":"Khorashad","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2011.09.006_bib49","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/gcc.20303","article-title":"Genomewide screening of DNA copy number changes in chronic myelogenous leukemia with the use of high-resolution array-based comparative genomic hybridization","volume":"45","author":"Hosoya","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.hoc.2011.09.006_bib50","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2010.65","article-title":"High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression","volume":"24","author":"Boultwood","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2011.09.006_bib51","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.leukres.2010.07.012","article-title":"Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients","volume":"35","author":"Joha","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2011.09.006_bib52","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s12185-011-0796-9","article-title":"Identification of copy number alterations by array comparative genomic hybridization in patients with late chronic or accelerated phase chronic myeloid leukemia treated with imatinib mesylate","volume":"93","author":"Nadarajan","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.hoc.2011.09.006_bib53","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/gcc.20611","article-title":"Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and\/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression?","volume":"47","author":"Deluche","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.hoc.2011.09.006_bib54","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2009-03-210377","article-title":"SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations","volume":"115","author":"Nowak","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib55","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1182\/blood-2005-01-0210","article-title":"Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment","volume":"105","author":"Schultheis","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib56","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/sj.leu.2404189","article-title":"BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry","volume":"20","author":"Hamilton","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2011.09.006_bib57","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.exphem.2008.11.005","article-title":"Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells","volume":"37","author":"Hamilton","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.hoc.2011.09.006_bib58","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2011.09.006_bib59","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3324\/haematol.2008.003715","article-title":"The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to\u00a0achieve a complete cytogenetic response on imatinib","volume":"94","author":"Khorashad","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2011.09.006_bib60","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1200\/JCO.2006.09.9499","article-title":"Measurement of in\u00a0vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia","volume":"25","author":"White","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.006_bib61","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/cncr.20457","article-title":"Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in\u00a0vitro incubation","volume":"101","author":"Cilloni","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2011.09.006_bib62","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","article-title":"Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate","volume":"108","author":"Jordanides","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib63","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/leu.2010.16","article-title":"Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity","volume":"24","author":"Engler","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2011.09.006_bib64","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.exphem.2009.02.006","article-title":"Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib","volume":"37","author":"Hatziieremia","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.hoc.2011.09.006_bib65","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1124\/dmd.109.031302","article-title":"Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib","volume":"38","author":"Dohse","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.hoc.2011.09.006_bib66","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib67","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hoc.2011.09.006_bib68","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib69","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.006_bib70","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/leu.2010.86","article-title":"hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia","volume":"24","author":"Bazeos","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2011.09.006_bib71","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","article-title":"Interaction of imatinib with human organic ion carriers","volume":"14","author":"Hu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2011.09.006_bib72","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.006_bib73","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","article-title":"hOCT 1 and resistance to imatinib","volume":"106","author":"Crossman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib74","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2009.166","article-title":"Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters","volume":"23","author":"Davies","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2011.09.006_bib75","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","article-title":"Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia","volume":"112","author":"Giannoudis","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib76","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.seminhematol.2010.06.001","article-title":"Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?","volume":"47","author":"Fava","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.hoc.2011.09.006_bib77","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1200\/JCO.2010.31.3619","article-title":"Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia","volume":"29","author":"Cortes","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.006_bib78","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/leu.2008.225","article-title":"A\u00a0population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials","volume":"22","author":"Lucas","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2011.09.006_bib79","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2011.09.006_bib80","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.006_bib81","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In\u00a0vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2011.09.006_bib82","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL","volume":"112","author":"Azam","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2011.09.006_bib83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2011.09.006_bib84","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","article-title":"BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study","volume":"359","author":"von Bubnoff","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2011.09.006_bib85","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.hoc.2011.09.006_bib86","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib87","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2011.09.006_bib88","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In\u00a0vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib89","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2011.09.006_bib90","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","article-title":"Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib91","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib92","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib","volume":"26","author":"Griswold","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.hoc.2011.09.006_bib93","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"The finding of kinase domain mutations in chronic phase CML patients responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.006_bib94","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment","volume":"105","author":"Chu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib95","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib96","doi-asserted-by":"crossref","first-page":"19466","DOI":"10.1073\/pnas.0609239103","article-title":"Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants","volume":"103","author":"Skaggs","year":"2006","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"27","key":"10.1016\/j.hoc.2011.09.006_bib97","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure\u2014does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib98","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1200\/JCO.2009.26.4945","article-title":"Comparative In\u00a0vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia","volume":"28","author":"Laneuville","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.006_bib99","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","article-title":"Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation","volume":"114","author":"Nicolini","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib100","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nsmb.1486","article-title":"Activation of tyrosine kinases by mutation of the gatekeeper threonine","volume":"15","author":"Azam","year":"2008","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.hoc.2011.09.006_bib101","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2010.030999","article-title":"Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy","volume":"96","author":"Hanfstein","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2011.09.006_bib102","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1182\/blood-2007-06-094508","article-title":"Interferon-{alpha} or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation","volume":"110","author":"de Lavallade","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib103","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2011.09.006_bib104","doi-asserted-by":"crossref","unstructured":"Cortes J, Talpaz M, Bixby D, et\u00a0al. A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. ASH Annual Meeting Abstracts. Orlando (FL), December 4\u20137, 2010;116: p. 210.","DOI":"10.1182\/blood.V116.21.210.210"},{"key":"10.1016\/j.hoc.2011.09.006_bib105","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.1182\/blood-2010-01-264234","article-title":"EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors","volume":"116","author":"Daghistani","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.006_bib106","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858811001031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858811001031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:55:36Z","timestamp":1760183736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858811001031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":106,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0889858811001031"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2011.09.006","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selection of Therapy: Rational Decisions Based on Molecular Events","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2011.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}